Modality
Bispecific Ab
MOA
CAR-T CD19
Target
IL-17A
Pathway
Proteasome
DLBCL
Development Pipeline
Preclinical
~Dec 2016
→ ~Mar 2018
Phase 1
~Jun 2018
→ ~Sep 2019
Phase 2
Dec 2019
→ Nov 2025
Phase 2Current
NCT07093445
318 pts·DLBCL
2019-12→2025-11·Recruiting
318 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-204mo agoPh2 Data· DLBCL
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2
Recruit…
Catalysts
Ph2 Data
2025-11-20 · 4mo ago
DLBCL
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07093445 | Phase 2 | DLBCL | Recruiting | 318 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A |